As the IP community waits for movement on the Biden Administration’s proposal to expand the scope of the march-in rights provision under the Bayh-Dole Act, the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) has been actively countering the administration’s argument that such a mechanism would effectively lower drug prices. The comment period for the National Institute of Standards & Technology (NIST) and the Department of Commerce’s Request for Information (RFI) on the proposal closed in early February. Since then, it has been rumored several times that the framework would be finalized and published, but those rumors never materialized.

Full Article Available Here